NEWS

Does my patient have HIT? There should be an application for that... And good news there is an application for that!

On July 13, the mobile app NomoHIT was formally launched on both iOS and Android platforms.
NomoHIT is the only user-friendly didactic mobile application that allows physicians and clinical lab specialists to evaluate how likely it is that an individual patient has HIT as a result of the HIT diagnostic workup.

NomoHIT computes the results of the 4Ts score and subsequent immunological and functional laboratory tests, to turn them into giving a probability of HIT diagnosis.
NomoHIT is intended to be used by health professionals and can be downloaded for free, on the AppStore and Google Play!

Discover NomoHIT : https://vu.fr/Bain

In September, EMOSIS and R2 Diagnostics joined forces to help in managing HIT in India through the formal launch of HIT Confirm. Emosis is thankful to R2 Diagnostics for this opportunity of growing HIT confirm market and their trust in the partnership.

On August 17, EMOSIS had the opportunity to participate in the 2022 edition of Thrombosis and Hemostasis Society of North America (THSNA) that was held in Chicago from August 16 to 18 . We were able to present a poster on the application of a statistical predictive model of heparin-induced thrombocytopenia (HIT).

This model demonstrates the potential of artificial intelligence in the diagnosis of HIT based on flow cytometry.

This year again, EMOSIS participated in the International Society on Thrombosis and Haemostasis (ISTH) congress which took place July 9 to 13, 2022, in London! The meeting was an opportunity to introduce NomoHIT to the international audience of hemostasis and thrombosis lab specialist through the presentation of the poster "Does my patient have an ISTH? There should be an app for that."

EMOSIS was pleased to participate in the French Congress of Hemostasis 2022 in Bordeaux, which took place from July 1st to 3rd.

Emosis introduced NomoHIT to the French clinical lab specialists managing HIT suspected patients.

Co-organized by the GFHT and CoMETH, this event covered the fields of hemorrhage, thrombosis, as well as pathophysiology and the development of new diagnostic or therapeutic approaches.